Sarah Bowdin

Sarah Bowdin

Auto-generated profile, based on publicly available information

Sarah Bowdin

Division of Genome Diagnostics, The Hospital for Sick Children

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2016 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
SBSarah Bowdin
Sarah Bowdin
AGAdel Gilbert
Adel Gilbert
EBEmma Bedoukian
Emma Bedoukian
CCChristopher Carew
Christopher Carew
MAMargaret P. Adam
Margaret P. Adam
IKIan D. Krantz
Ian D. Krantz
The introduction of diagnostic clinical genome and exome sequencing (CGES) is changing the scope of practice for clinical geneticists. Many large institutions are making a significant investment in infrastructure and technology, allowing clinicians to access CGES, especially as health-care coverage begins to extend to clinically indicated genomic sequencing-based tests. Translating and realizing the comprehensive clinical benefits of genomic medicine remain a key challenge for the current and future care of patients. With the increasing application of CGES, it is necessary for geneticists and other health-care providers to understand its benefits and limitations in order to interpret the clinical relevance of genomic variants identified in the context of health and disease. New, collaborative working relationships with specialists across diverse disciplines (e.g., clinicians, laboratorians, bioinformaticians) will undoubtedly be key attributes of the future practice of clinical genetics and may serve as an example for other specialties in medicine. These new skills and relationships will also inform the development of the future model of clinical genetics training curricula. To address the evolving role of the clinical geneticist in the rapidly changing climate of genomic medicine, two Clinical Genetics Think Tank meetings were held that brought together physicians, laboratorians, scientists, genetic counselors, trainees, and patients with experience in clinical genetics, genetic diagnostics, and genetics education. This article provides recommendations that will guide the integration of genomics into clinical practice. Genet Med 18 11, 1075–1084.

5 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
HHHuayun Hou
Huayun Hou
KYKyoko E. Yuki
Kyoko E. Yuki
GCGregory Costain
Gregory Costain
ASAnna Szuto
Anna Szuto
SBSierra Barnes
Sierra Barnes
LKLianna Kyriakopoulou
Lianna Kyriakopoulou
Despite advances in diagnostic testing and genome sequencing, the majority of individuals with rare genetic disorders remain undiagnosed. As a complement to genome sequencing, transcriptional profiling can provide insight into the functional consequences of DNA variants on RNA transcript expression and structure. Here we assessed the utility of blood derived RNA-seq in a well-studied, but still mostly undiagnosed, cohort of individuals who enrolled in the SickKids Genome Clinic study. This cohort was established to benchmark the ability of genome sequencing technologies to diagnose genetic diseases and has been subjected to multiple analyses. We used RNA-seq to profile whole blood RNA expression from all probands for whom a blood sample was available (n=134). Our RNA-centric analysis included differential gene expression, alternative splicing, and allele specific expression. In one third of the diagnosed individuals (20/61), RNA-seq provided additional evidence supporting the pathogenicity of the variant found by prior DNA-based analyses. In 2/61 cases, RNA-seq changed the GS-derived genetic diagnosis ( EPG5 to LZTR1 in an individual with a Noonan syndrome-like disorder) and discovered an additional relevant gene ( CEP120 in addition to SON in an individual with ZTTK syndrome). In ∼7% (5/73) of the undiagnosed participants, RNA-seq provided at least one plausible, potentially diagnostic candidate gene. This study illustrates the benefits and limitations of using whole-blood RNA profiling to support existing molecular diagnoses and reveal candidate molecular mechanisms underlying undiagnosed genetic disease.